GlassScriptPhysician profile
Jonathan D Kelly
NPI 1053529446
$3,181.60
in general payments reported to CMS, 2019-2025
24 companies · $469 in 2025
The $469 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,101 · 2022: $553 · 2023: $508 · 2024: $551 · 2025: $469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,527.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $380.70 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $344.02 | 2021-2025 | Breztri, Farxiga |
| Astellas Pharma US INC | $334.99 | 2021-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $325.23 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Biohaven Pharmaceuticals, INC. | $289.77 | 2021 | |
| Abbvie INC. | $263.87 | 2021-2025 | |
| Novo Nordisk INC | $203.44 | 2021-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $198.40 | 2023-2025 | |
| Amgen INC. | $100.60 | 2021-2023 | Prolia, Evenity |
| Janssen Pharmaceuticals, INC | $97.24 | 2021-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $88.72 | 2021-2024 | Gardasil 9, Gardasil, Vaxelis |
| Glaxosmithkline, LLC. | $75.77 | 2022-2024 | Shingrix, Bexsero, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.85 | 2022-2025 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $64.88 | 2022-2023 | |
| Idorsia Pharmaceuticals US INC | $53.19 | 2022-2023 | Quviviq |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $50.20 | 2022 | |
| Insulet Corporation | $46.57 | 2025 | Omnipod |
| Lundbeck LLC | $46.21 | 2021-2023 | Vyepti |
| Exact Sciences Corporation | $39.29 | 2024 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $35.25 | 2021 | |
| Sanofi-Aventis U.S. LLC | $33.47 | 2023 | |
| Dexcom, INC. | $16.12 | 2023 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $14.02 | 2024 | Intracept |
| Medtronic, INC. | $13.80 | 2023 | Minimed 780g |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Kelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.